Baltic Conference of Hematology 2018

Baltic Conference of Hematology 2018

Programme

Invited Speakers

Harald Holte
Tatyana Ionova
Anna Porwit
Tadeusz Robak
Martin Hutchings
Steven Treon
Ewa Kimby
Mervi Taskinen
Karin Mellgren
Evangelos Terpos


Topics of the 11th Baltic Conference of Hematology :
  • Acute lymphoblastic leukemia
  • Hodgkin’s lymphoma
  • Non-Hodgkin’s lymphoma
  • Chronic lymphocytic leukemia
  • Waldenström’s macroglobulinemia
  • Myeloma

Friday, 19 October


12:00-14:00Registration Open
14:00-15:00Congress Opening Ceremony. European Hematology Association (EHA)- Estonian Society of Hematology Joint Session
15:00-15:45Chair: Kadri Saks
Sanofi satellite session: Application of Next-Generation Sequencing (NGS)-based genetic screenings to hematologic disease: the case of lysosomal storage disorders and their differential diagnoses - Francisco J.del Castillo
15:45-16:00Coffee break
16:00-17:30Session I - ALL Chair: Kadri Saks, Mari Punab

16:00-16:30 Update on Minimal Residual Disease in ALL - Anna Porwit
16:30-17:00 New trends in ALL therapy: what is changing with ALLTogether - Mervi Taskinen
17:00-17:15 Acute de novo lymphoblastic leukemia in adults in Estonia during 2007-2017: incidence, treatment modalities and survival - Mari Punab
17:15-17:30 Cytokine receptor and kinase signaling pathway activating alterations in pediatric and adult B-other ALL - Rimvydas Norvilas
17:30-17:45 Acute lymphoblastic leukemia (ALL) in Estonian children from 2008 to 2018: 10 year treatment results with NOPHO ALL-2008 protocol - Maarja Karu
17:45-18:30Chair: Mariken Ross
Pfizer Satellite session: Antibody directed approached in acute lymphoid leukemias - David Marks
Invitation to Pfizer Satellite Session in PDF-format.
20:00-22:00Welcome reception at Seaplane Harbor of Maritime Museum, Vesilennuki tee 6, Tallinn. Transfer to the reception venue will leave 19:45 infront of Radisson Blu Sky Hotel. Transfer back to hotel will leave at 22:00

Saturday, 20 October


08:00-09:30 II session: CLL/ hematological malignancies
Chair: Iige Viigimaa, Sandra Lejniece

08:00-8:30 CLL: an update with focus on conventional therapy Eva Kimby
08:30-9:00 Current diagnostic and therapeutic recommendations for CLL - Tadeusz Robak
9:00-9:15 First results of Venetoclax in combination with low dose Cytarabine or Actinomycin D in relapsed/refractory acute leukemia patients - Andrius Zucenka
09:15-9:30 Time from symptom onset to diagnosis and treatment among hematological malignancies: influencing factors and associated negative outcomes - Austeja Dapkeviciute
09:30-09:45Coffee break
09:45-11:15 Session III - Lymphoma I
Chair: Ugne Ringeleviciute, Hele Everaus

09:45-10:15 CAR019 therapy in relapsed Diffuse large B-cell lymphomas: Experience from an international multicenter study - Harald Holte
10:15-10:45 Children's non-Hodgkin lymphoma – actual status of treatment studies in the European Intergroup - Karin Mellgren
10:45-11:00 Epidemiology and treatment of HIV-associated lymphomas in Estonia - Iige Viigimaa
11:00-11:15 The spectrum of lymphoproliferative diseases in Lithuania 2010-2016: how are we different from the west? - Ugne Ringeleviciute
11:15-11:30Coffee break
11:30-13:05 IV sessioon: Plasma Cell disorders, including Waldenström's Macroglobulinemia
Chair:Valdas Peceliunas, Evangelos Terpos

11:30-12:00 Genomic and Treatment Advances in Waldenstrom’s Macroglobulinemia - Steven Treon
12:00-12:30 Optimal sequencing of treatment for ASCT non eligible patients - Evangelos Terpos
12:30-12:45 Genomic Instability in Multiple Myeloma - Edward Laane
12:45-13:05 Systems Medicine Approach for Individualized Management of Lymphoproliferative Malignancies-a Novel Way for the Progress? - Hele Everaus
13:05-14:00Lunch
14:00-15:00Chair:Iige Viigimaa
Janssen satellit session: Clinical Approach to Patients with High Molecular Risk Chronic Lymphocytic Leukemia - Davide Rossi
15:05-17:00V sessioon: Lymfoma II
Chair:Edward Laane, Ilze Trociukas

15:05-15:35 1st line and PET-response adapted treatment in Hodgkin's lymphoma
- Martin Hutchings 15:35-16:05 Treatment of relapsed/refractory Hodgkin's lymphoma - Martin Hutchings
16:05-16:35 Assessing patient-reported outcomes in lymphoma patients: why, when and how. - Tatyana Ionova
16:35-16:50 B follicular lymphoma in Lithuania 2008-2017: incidence, evolution, survival - Ugne Ringeleviciute
16:50-17:05 Brentuximab vedotin and nivolumab in relapsed/refractory Hodgkin lymphoma: Estonian experience - Julia Abubikirova
17:05-17:20 Conclusions from the day



Last update 26.02.2019 16:17